Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Natera, Inc. (NTRA)
USD272.89
+2.94 (+1.09%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
13011 McCallen Pass Building A 78753
Austin, CA, US
Austin, CA, US
CEO
Steven Leonard Chapman
Website
natera.com
IPO
2015-07-01
CIK 1604821 ISIN US6323071042
Description
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
News Sentiment (7d)
3 articles
- NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers Zacks Investment Research
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers Business Wire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD272.89
+2.94 (+1.09%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.51
Float Shares
134.65M
Free Float %
95.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.55% | -5.24% | +5.79% | -1.75% | -2.53% | -10.86% | +29.83% | +299.63% | +134.29% | +1,708.77% | +1,034.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (27 ratings, all time)
Buy
Price Targets & DCF
Current price
272.89
Low
220.00
-19.4%
Consensus
263.78
-3.3%
Median
270.00
-1.1%
High
285.00
+4.4%
Ratings Trend (MoM)
89% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | -1 |
| Buy | 13 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
251.67
-7.8%
|
| Last Quarter | 3 |
251.67
-7.8%
|
| Last Year | 13 |
241.54
-11.5%
|
| All Time | 34 |
167.09
-38.8%
|
Quality scores
Altman Z-Score
20.45
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+35.9% ★ Q1'26: +38.8% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+0.7% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-6.0% Q1'26: +2.6% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-11.5% Q1'26: -13.4% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-31.0% Q1'26: -40.4% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+9.6% Q1'26: +5.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.81× Q1'26: -0.82× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 10 EPS Ana. |
Dec 2027 14 Rev. Ana. 9 EPS Ana. |
Dec 2028 11 Rev. Ana. 12 EPS Ana. |
Dec 2029 5 Rev. Ana. 10 EPS Ana. |
Dec 2030 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
190.36M
est: 182.96M (+4.0%)
|
217.07M
est: 217.82M (-0.3%)
|
210.94M
est: 214.35M (-1.6%)
|
257.65M
est: 254.51M (+1.2%)
|
302.33M
est: 296.92M (+1.8%)
|
391.01M
est: 385.24M (+1.5%)
|
625.49M
est: 621.43M (+0.7%)
|
820.22M
est: 819.43M (+0.1%)
|
1.08B
est: 1.36B (-20.4%)
|
1.70B
est: 1.65B (+2.7%)
|
2.31B
est: 2.24B (+2.8%)
|
2.74B
2.66B – 2.75B
+22.0% YoY
|
3.21B
3.13B – 3.32B
+17.3% YoY
|
3.89B
3.82B – 3.96B
+21.3% YoY
|
4.53B
4.41B – 4.68B
+16.5% YoY
|
5.13B
4.99B – 5.30B
+13.1% YoY
|
| EBITDA |
-61.24M
est: -84.46M (+27.5%)
|
-93.37M
est: -100.55M (+7.1%)
|
-125.82M
est: -98.95M (-27.2%)
|
-107.13M
est: -117.49M (+8.8%)
|
-104.41M
est: -125.33M (+16.7%)
|
-205.95M
est: -163.24M (-26.2%)
|
-451.54M
est: -380.27M (-18.7%)
|
-507.03M
est: -380.77M (-33.2%)
|
-383.28M
est: -515.86M (+25.7%)
|
-148.08M
est: -626.34M (+76.4%)
|
-264.02M
est: -850.38M (+69.0%)
|
-1.04B
-1.04B – -1.01B
-22.0% YoY
|
-1.22B
-1.26B – -1.19B
-17.3% YoY
|
-1.48B
-1.50B – -1.45B
-21.3% YoY
|
-1.72B
-1.78B – -1.67B
-16.5% YoY
|
-1.94B
-2.01B – -1.89B
-13.1% YoY
|
| EBIT |
-66.77M
est: -89.25M (+25.2%)
|
-99.65M
est: -106.26M (+6.2%)
|
-132.96M
est: -104.57M (-27.2%)
|
-114.63M
est: -124.16M (+7.7%)
|
-112.14M
est: -139.80M (+19.8%)
|
-214.56M
est: -172.73M (-24.2%)
|
-462.79M
est: -395.13M (-17.1%)
|
-537.50M
est: -392.13M (-37.1%)
|
-421.89M
est: -545.54M (+22.7%)
|
-179.05M
est: -662.38M (+73.0%)
|
-264.02M
est: -899.30M (+70.6%)
|
-1.10B
-1.10B – -1.07B
-22.0% YoY
|
-1.29B
-1.33B – -1.25B
-17.3% YoY
|
-1.56B
-1.59B – -1.53B
-21.3% YoY
|
-1.82B
-1.88B – -1.77B
-16.5% YoY
|
-2.06B
-2.12B – -2.00B
-13.1% YoY
|
| Net Income |
-70.28M
est: -267.31M (+73.7%)
|
-95.77M
est: -209.53M (+54.3%)
|
-136.31M
est: -272.09M (+49.9%)
|
-128.15M
est: -277.50M (+53.8%)
|
-124.83M
est: -150.12M (+16.8%)
|
-229.74M
est: -182.75M (-25.7%)
|
-471.72M
est: -398.29M (-18.4%)
|
-547.80M
est: -511.79M (-7.0%)
|
-434.80M
est: -335.56M (-29.6%)
|
-190.43M
est: -192.37M (+1.0%)
|
-208.16M
est: -328.45M (+36.6%)
|
-245.31M
-292.31M – -171.63M
+25.3% YoY
|
-59.18M
-7.72B – 2.68B
+75.9% YoY
|
159.05M
-251.07M – 780.46M
+368.7% YoY
|
300.51M
290.18M – 313.49M
+88.9% YoY
|
642.13M
620.06M – 669.86M
+113.7% YoY
|
| SGA |
109.64M
est: 123.61M (-11.3%)
|
136.13M
est: 147.16M (-7.5%)
|
155.31M
est: 144.82M (+7.2%)
|
154.87M
est: 171.95M (-9.9%)
|
206.18M
est: 253.07M (-18.5%)
|
303.63M
est: 251.42M (+20.8%)
|
511.03M
est: 452.53M (+12.9%)
|
588.59M
est: 392.53M (+49.9%)
|
618.31M
est: 846.79M (-27.0%)
|
841.31M
est: 1.03B (-18.2%)
|
1.18B
est: 1.40B (-15.7%)
|
1.70B
1.66B – 1.71B
+22.0% YoY
|
2.00B
1.95B – 2.07B
+17.3% YoY
|
2.42B
2.38B – 2.46B
+21.3% YoY
|
2.82B
2.75B – 2.92B
+16.5% YoY
|
3.19B
3.11B – 3.30B
+13.1% YoY
|
| EPS |
-1.47
est: -2.14 (+31.4%)
|
-1.86
est: -1.68 (-10.7%)
|
-2.56
est: -2.18 (-17.3%)
|
-2.22
est: -2.23 (+0.2%)
|
-1.79
est: -1.89 (+5.1%)
|
-2.84
est: -2.54 (-11.9%)
|
-5.21
est: -5.02 (-3.8%)
|
-5.57
est: -5.60 (+0.6%)
|
-3.78
est: -2.44 (-54.7%)
|
-1.53
est: -1.50 (-2.2%)
|
-1.52
est: -2.40 (+36.6%)
|
-1.68
-2.14 – -1.26
+30.0% YoY
|
-0.38
-56.45 – 19.58
+77.1% YoY
|
1.29
-1.84 – 5.71
+436.7% YoY
|
2.20
2.12 – 2.29
+70.0% YoY
|
4.70
4.54 – 4.90
+113.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-08 | Evercore ISI Group | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
199.23M
OE per share TTM
1.44
Owner's Yield
0.72%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
16.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
254
Total invested
1.37B
Insider transactions (90d)
28
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 8.24M | 6.70% | — | — | 8.24M | — | HC | Delaware | 2024-11-08 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 7.79M | 8.23% | — | 49.5K | 7.66M | 125.8K | IA | Pennsylvania | 2022-02-10 | ↗ |
| 3 | 13-3017981 | 6.81M | 7.20% | 6.81M | — | 6.81M | — | HC | York | 2022-02-14 | ↗ |
| 4 | of 9 Pages | 6.77M | 13.50% | — | — | — | 6.77M | PN | DELAWARE | 2016-02-12 | ↗ |
| 5 | Alger Group Holdings, LLC | 6.22M | 7.28% | 6.22M | — | 6.22M | — | HC | New York | 2021-02-16 | ↗ |
| 6 | Fred Alger Management, LLC | 5.49M | 6.43% | 5.49M | — | 5.49M | — | IA | New York | 2021-02-16 | ↗ |
| 7 | Matthew Rabinowitz | 5.23M | 10.00% | 4.61M | 613.5K | 4.61M | 613.5K | IN | USA | 2016-02-12 | ↗ |
| 8 | JPMORGAN CHASE & CO.13-2624428 | 5.03M | 5.30% | 4.52M | 27.6K | 4.99M | 29.9K | HC | Delaware | 2022-01-24 | ↗ |
| 9 | Capital World Investors ** | 4.77M | 6.10% | 4.77M | — | 4.77M | — | IA | Delaware | 2020-02-14 | ↗ |
| 10 | Dr. James I. Healy | 3.14M | 4.10% | 40.8K | 3.10M | 40.8K | 3.10M | IN | U.S. Citizen | 2020-02-13 | ↗ |
| 11 | Dr. Michael F. Powell (“Powell”) | 3.10M | 4.00% | — | 3.10M | — | 3.10M | IN | U.S. Citizen | 2020-02-13 | ↗ |
| 12 | Company, L.P. | 2.78M | 5.17% | — | 2.78M | — | — | PN | Delaware | 2017-12-11 | ↗ |
| 13 | James E. Flynn | 2.78M | 5.17% | — | 2.78M | — | — | IN | United States | 2017-12-11 | ↗ |
| 14 | L.P. | 2.78M | 5.17% | — | 2.78M | — | — | PN | Delaware | 2017-12-11 | ↗ |
| 15 | Sofinnova Management IX, L.L.C. | 1.55M | 2.00% | 1.55M | — | 1.55M | 10.00 | OO | Delaware | 2020-02-13 | ↗ |
| 16 | Sofinnova Management VIII, L.L.C. | 1.55M | 2.00% | 1.55M | — | 1.55M | 10.00 | OO | Delaware | 2020-02-13 | ↗ |
| 17 | Sofinnova Venture Partners IX, L.P. (“SVP IX”) | 1.55M | 2.00% | 1.55M | — | 1.55M | — | PN | Delaware | 2020-02-13 | ↗ |
| 18 | Sofinnova Venture Partners VIII, L.P. (“SVP VIII”) | 1.55M | 2.00% | 1.55M | — | 1.55M | — | PN | Delaware | 2020-02-13 | ↗ |
| 19 | Master Fund, L.P. | 981.2K | 1.82% | — | 981.2K | — | — | PN | British Virgin Islands | 2017-12-11 | ↗ |
| 20 | Page 4 of 9 Pages | 723.3K | 1.40% | — | — | — | 723.3K | OO | DELAWARE | 2016-02-12 | ↗ |
| 21 | Ravi Mhatre | 37.9K | 0.07% | 37.9K | — | 37.9K | — | IN | United States of America | 2017-02-14 | ↗ |
| 22 | Barry Eggers | — | 0.00% | — | — | — | — | IN | United States of America | 2017-02-14 | ↗ |
| 23 | Christopher J. Schaepe | — | 0.00% | — | — | — | — | IN | United States of America | 2017-02-14 | ↗ |
| 24 | Lightspeed General Partner VIII, L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2017-02-14 | ↗ |
| 25 | Lightspeed Ultimate General Partner VIII, Ltd. | — | 0.00% | — | — | — | — | OO | Cayman Islands | 2017-02-14 | ↗ |
| 26 | Lightspeed Venture Partners VIII, L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2017-02-14 | ↗ |
| 27 | Peter Y. Nieh | — | 0.00% | — | — | — | — | IN | United States of America | 2017-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
254
-550 vs prev Q
New positions
30
Closed positions
555
Increased
134
Reduced
82
Put/Call ratio
0.00
Calls held
300.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | JPMORGAN CHASE & CO | 12.85M +1.2M (+10.5%) | 2.94B +1.1B (+57.3%) | 9.37% +0.844 pp | 0.18% +0.073 pp | USD132.79 +72.5% | 33 qtrs — |
| 2 | VANGUARD GROUP INC | 12.31M -82.6K (-0.7%) | 2.82B +825.0M (+41.4%) | 8.97% -0.113 pp | 0.04% +0.011 pp | USD49.86 +359.5% | 42 qtrs — |
| 3 | PRICE T ROWE ASSOCIATES INC /MD/ | 10.87M -1.1M (-9.0%) | 2.49B +567.5M (+29.5%) | 7.92% -0.835 pp | 0.27% +0.063 pp | USD144.05 +59.0% | 30 qtrs — |
| 4 | BLACKROCK, INC. | 10.86M -104.9K (-1.0%) | 2.49B +722.9M (+41.0%) | 7.92% -0.123 pp | 0.04% +0.011 pp | USD133.32 +71.8% | 6 qtrs — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 4.98M +2.4M (+94.7%) | 1.14B +728.6M (+177.1%) | 3.63% +1.753 pp | 0.20% +0.128 pp | USD176.03 +30.1% | 7 qtrs — |
| 6 | FARALLON CAPITAL MANAGEMENT LLC | 3.91M -339.1K (-8.0%) | 896.74M +212.1M (+31.0%) | 2.85% -0.265 pp | 4.23% +1.429 pp | USD74.68 +206.8% | 19 qtrs — |
| 7 | STATE STREET CORP | 3.23M -163.7K (-4.8%) | 739.02M +193.4M (+35.4%) | 2.35% -0.134 pp | 0.02% +0.006 pp | USD68.40 +234.9% | 42 qtrs — |
| 8 | COATUE MANAGEMENT LLC | 2.63M +2.5M (+1,446.1%) | 603.27M +575.9M (+2,100.3%) | 1.92% +1.795 pp | 1.51% +1.442 pp | USD224.68 +2.0% | 2 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.61M +11.7K (+0.5%) | 596.08M +178.4M (+42.7%) | 1.90% -0.003 pp | 0.04% +0.010 pp | USD76.27 +200.4% | 42 qtrs — |
| 10 | AQR CAPITAL MANAGEMENT LLC | 2.60M +199.2K (+8.3%) | 595.47M +209.1M (+54.1%) | 1.89% +0.135 pp | 0.31% +0.065 pp | USD147.87 +54.9% | 11 qtrs — |
| 11 | FRANKLIN RESOURCES INC | 2.53M -130.5K (-4.9%) | 580.64M +151.7M (+35.4%) | 1.85% -0.107 pp | 0.14% +0.036 pp | USD134.94 +69.8% | 12 qtrs — |
| 12 | DUQUESNE FAMILY OFFICE LLC | 2.51M -703.2K (-21.9%) | 575.33M +57.9M (+11.2%) | 1.83% -0.526 pp | 12.80% +0.062 pp | USD99.19 +131.0% | 14 qtrs — |
| 13 | CASTLE HOOK PARTNERS LP | 2.17M +420.6K (+24.1%) | 496.64M +215.4M (+76.6%) | 1.58% +0.299 pp | 2.06% +0.638 pp | USD144.48 +58.6% | 8 qtrs — |
| 14 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.05M +20.9K (+1.0%) | 469.17M +142.9M (+43.8%) | 1.49% +0.007 pp | 0.15% +0.050 pp | USD91.06 +151.6% | 9 qtrs — |
| 15 | FRED ALGER MANAGEMENT, LLC | 1.82M -629.3K (-25.7%) | 417.52M +22.9M (+5.8%) | 1.33% -0.469 pp | 1.64% +0.102 pp | USD54.58 +319.7% | 31 qtrs — |
| 16 | NORGES BANK | 1.63M +1.6M (+100.0%) | 372.40M +372.4M (+100.0%) | 1.18% +1.185 pp | 0.04% +0.040 pp | USD229.09 +0.0% | 1 qtrs NEW |
| 17 | SOFINNOVA INVESTMENTS, INC. | 1.55M +— (+0.0%) | 355.15M +105.6M (+42.3%) | 1.13% -0.007 pp | 15.31% +1.668 pp | USD9.35 +2,350.2% | 32 qtrs — |
| 18 | RTW INVESTMENTS, LP | 1.50M -500.0K (-25.0%) | 343.64M +21.7M (+6.7%) | 1.09% -0.373 pp | 3.44% -0.525 pp | USD42.81 +435.1% | 26 qtrs — |
| 19 | FMR LLC | 1.48M +362.6K (+32.6%) | 338.13M +158.9M (+88.7%) | 1.08% +0.260 pp | 0.02% +0.008 pp | USD125.34 +82.8% | 30 qtrs — |
| 20 | CAPITAL WORLD INVESTORS | 1.43M +20.4K (+1.4%) | 328.31M +100.9M (+44.4%) | 1.04% +0.009 pp | 0.04% +0.014 pp | USD128.83 +77.8% | 42 qtrs — |
| 21 | INVESCO LTD. | 1.33M +108.4K (+8.9%) | 304.50M +108.0M (+55.0%) | 0.97% +0.074 pp | 0.05% +0.016 pp | USD88.73 +158.2% | 28 qtrs — |
| 22 | MORGAN STANLEY | 1.23M -49.2K (-3.8%) | 282.73M +76.2M (+36.9%) | 0.90% -0.041 pp | 0.02% +0.004 pp | USD72.27 +217.0% | 42 qtrs — |
| 23 | LORD, ABBETT & CO. LLC | 1.22M +110.7K (+10.0%) | 279.27M +100.9M (+56.5%) | 0.89% +0.076 pp | 0.86% +0.326 pp | USD115.35 +98.6% | 26 qtrs — |
| 24 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.18M +621.0K (+111.1%) | 270.31M +180.3M (+200.4%) | 0.86% +0.450 pp | 0.16% +0.102 pp | USD194.45 +17.8% | 7 qtrs — |
| 25 | FEDERATED HERMES, INC. | 1.02M +222.2K (+27.9%) | 233.49M +105.2M (+82.0%) | 0.74% +0.159 pp | 0.39% +0.164 pp | USD124.97 +83.3% | 27 qtrs — |
| 26 | MAVERICK CAPITAL LTD | 944.0K -388.7K (-29.2%) | 216.27M +1.7M (+0.8%) | 0.69% -0.289 pp | 2.32% -0.546 pp | USD110.04 +108.2% | 8 qtrs — |
| 27 | BANK OF AMERICA CORP /DE/ | 875.4K +114.1K (+15.0%) | 200.54M +78.0M (+63.6%) | 0.64% +0.080 pp | 0.01% +0.006 pp | USD122.19 +87.5% | 42 qtrs — |
| 28 | GILDER GAGNON HOWE & CO LLC | 828.3K -130.7K (-13.6%) | 189.76M +35.4M (+22.9%) | 0.60% -0.099 pp | 2.00% +0.430 pp | USD63.09 +263.1% | 26 qtrs — |
| 29 | CLEARBRIDGE INVESTMENTS, LLC | 790.1K -11.3K (-1.4%) | 181.00M +52.0M (+40.3%) | 0.58% -0.012 pp | 0.14% +0.048 pp | USD159.66 +43.5% | 5 qtrs — |
| 30 | NORTHERN TRUST CORP | 775.8K +29.4K (+3.9%) | 177.72M +57.6M (+47.9%) | 0.57% +0.018 pp | 0.02% +0.007 pp | USD77.83 +194.3% | 42 qtrs — |
| 31 | NWI MANAGEMENT LP | 762.6K -67.7K (-8.2%) | 174.71M +41.1M (+30.7%) | 0.56% -0.053 pp | 8.04% +0.919 pp | USD135.45 +69.1% | 7 qtrs — |
| 32 | UBS ASSET MANAGEMENT AMERICAS INC | 741.7K -20.6K (-2.7%) | 169.93M +47.2M (+38.5%) | 0.54% -0.018 pp | 0.04% +0.009 pp | USD120.36 +90.3% | 30 qtrs — |
| 33 | ARK INVESTMENT MANAGEMENT LLC | 731.1K -161.5K (-18.1%) | 167.49M +23.8M (+16.6%) | 0.53% -0.122 pp | 1.11% +0.256 pp | USD120.94 +89.4% | 8 qtrs — |
| 34 | GOLDMAN SACHS GROUP INC | 716.8K -384.7K (-34.9%) | 164.21M -13.1M (-7.4%) | 0.52% -0.285 pp | 0.02% -0.002 pp | USD134.31 +70.6% | 42 qtrs — |
| 35 | POINTSTATE CAPITAL LP | 715.5K -410.9K (-36.5%) | 163.91M -17.4M (-9.6%) | 0.52% -0.304 pp | 2.41% -0.293 pp | USD156.33 +46.5% | 7 qtrs — |
| 36 | WESTFIELD CAPITAL MANAGEMENT CO LP | 714.7K +138.9K (+24.1%) | 163.73M +71.0M (+76.6%) | 0.52% +0.099 pp | 0.68% +0.293 pp | USD169.00 +35.6% | 5 qtrs — |
| 37 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 711.4K -172.1K (-19.5%) | 162.97M +20.8M (+14.6%) | 0.52% -0.129 pp | 0.10% +0.014 pp | USD117.81 +94.5% | 8 qtrs — |
| 38 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 674.4K +27.0K (+4.2%) | 154.50M +50.3M (+48.3%) | 0.49% +0.017 pp | 0.02% +0.007 pp | USD78.64 +191.3% | 42 qtrs — |
| 39 | BANK OF NEW YORK MELLON CORP | 652.9K +14.0K (+2.2%) | 149.58M +46.7M (+45.4%) | 0.48% +0.008 pp | 0.03% +0.007 pp | USD63.62 +260.1% | 42 qtrs — |
| 40 | DRIEHAUS CAPITAL MANAGEMENT LLC | 625.9K +39.7K (+6.8%) | 143.39M +49.0M (+52.0%) | 0.46% +0.027 pp | 0.97% +0.298 pp | USD88.82 +157.9% | 14 qtrs — |
| 41 | RAYMOND JAMES FINANCIAL INC | 614.2K -36.6K (-5.6%) | 141.14M +36.4M (+34.7%) | 0.45% -0.030 pp | 0.04% +0.010 pp | USD158.30 +44.7% | 5 qtrs — |
| 42 | CHEVY CHASE TRUST HOLDINGS, LLC | 582.0K -16.8K (-2.8%) | 133.33M +36.9M (+38.3%) | 0.42% -0.015 pp | 0.36% +0.095 pp | USD115.74 +97.9% | 8 qtrs — |
| 43 | VICTORY CAPITAL MANAGEMENT INC | 556.7K -36.6K (-6.2%) | 127.54M +32.0M (+33.5%) | 0.41% -0.029 pp | 0.07% +0.016 pp | USD137.36 +66.8% | 26 qtrs — |
| 44 | D. E. SHAW & CO., INC. | 553.6K +421.5K (+318.9%) | 126.83M +105.6M (+496.2%) | 0.40% +0.307 pp | 0.07% +0.058 pp | USD190.23 +20.4% | 24 qtrs — |
| 45 | AMERICAN CENTURY COMPANIES INC | 540.7K -302.7K (-35.9%) | 123.87M -11.9M (-8.8%) | 0.39% -0.224 pp | 0.06% -0.007 pp | USD86.28 +165.5% | 27 qtrs — |
| 46 | FRONTIER CAPITAL MANAGEMENT CO LLC | 521.8K +152.7K (+41.4%) | 119.53M +60.1M (+101.2%) | 0.38% +0.110 pp | 1.27% +0.736 pp | USD111.17 +106.1% | 27 qtrs — |
| 47 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 498.4K +498.3K (+2,768,561.1%) | 114.17M +114.2M (+3,805,566.7%) | 0.36% +0.363 pp | 0.07% +0.072 pp | USD229.09 +0.0% | 2 qtrs — |
| 48 | NUVEEN, LLC | 479.2K -174.9K (-26.7%) | 109.78M +4.5M (+4.3%) | 0.35% -0.130 pp | 0.03% +0.001 pp | USD141.41 +62.0% | 4 qtrs — |
| 49 | AGF MANAGEMENT LTD | 474.1K +466.8K (+6,371.9%) | 108.62M +107.4M (+9,110.7%) | 0.35% +0.340 pp | 0.47% +0.466 pp | USD227.24 +0.8% | 8 qtrs — |
| 50 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 471.1K -157.5K (-25.1%) | 107.84M +6.7M (+6.6%) | 0.34% -0.118 pp | 1.25% +0.266 pp | USD110.91 +106.6% | 8 qtrs — |
| 51 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 454.5K -20.9K (-4.4%) | 104.01M +27.2M (+35.4%) | 0.33% -0.017 pp | 0.17% +0.045 pp | USD80.07 +186.1% | 17 qtrs — |
| 52 | UBS GROUP AG | 438.9K +71.4K (+19.4%) | 100.54M +41.4M (+70.0%) | 0.32% +0.050 pp | 0.02% +0.007 pp | USD132.78 +72.5% | 42 qtrs — |
| 53 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 407.7K +284.1K (+229.9%) | 93.39M +73.5M (+369.4%) | 0.30% +0.207 pp | 1.94% +1.529 pp | USD196.38 +16.7% | 8 qtrs — |
| 54 | PANAGORA ASSET MANAGEMENT INC | 393.4K +117.0K (+42.3%) | 90.13M +45.6M (+102.5%) | 0.29% +0.084 pp | 0.32% +0.140 pp | USD182.09 +25.8% | 5 qtrs — |
| 55 | WELLS FARGO & COMPANY/MN | 384.8K +95.5K (+33.0%) | 88.15M +41.6M (+89.3%) | 0.28% +0.068 pp | 0.02% +0.007 pp | USD166.37 +37.7% | 42 qtrs — |
| 56 | QUBE RESEARCH & TECHNOLOGIES LTD | 367.9K +16.2K (+4.6%) | 84.27M +27.7M (+48.9%) | 0.27% +0.010 pp | 0.09% +0.027 pp | USD148.86 +53.9% | 12 qtrs — |
| 57 | ORBIMED ADVISORS LLC | 365.8K -63.5K (-14.8%) | 83.80M +14.7M (+21.3%) | 0.27% -0.048 pp | 1.72% +0.089 pp | USD68.10 +236.4% | 42 qtrs — |
| 58 | LEGAL & GENERAL GROUP PLC | 363.1K +27.1K (+8.1%) | 83.19M +29.1M (+53.8%) | 0.26% +0.018 pp | 0.02% +0.006 pp | USD127.31 +79.9% | 39 qtrs — |
| 59 | SWISS NATIONAL BANK | 357.2K -16.7K (-4.5%) | 81.83M +21.6M (+36.0%) | 0.26% -0.014 pp | 0.05% +0.014 pp | USD86.67 +164.3% | 39 qtrs — |
| 60 | DIMENSIONAL FUND ADVISORS LP | 350.9K -11.9K (-3.3%) | 80.39M +22.0M (+37.6%) | 0.26% -0.010 pp | 0.02% +0.004 pp | USD106.05 +116.0% | 22 qtrs — |
| 61 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 343.8K +338.1K (+5,965.1%) | 78.75M +77.8M (+8,531.7%) | 0.25% +0.246 pp | 0.11% +0.111 pp | USD227.65 +0.6% | 4 qtrs — |
| 62 | VOYA INVESTMENT MANAGEMENT LLC | 336.5K -20.1K (-5.6%) | 77.08M +19.7M (+34.3%) | 0.25% -0.016 pp | 0.08% +0.019 pp | USD74.56 +207.3% | 39 qtrs — |
| 63 | AMERIPRISE FINANCIAL INC | 335.3K +27.0K (+8.8%) | 76.82M +27.2M (+54.8%) | 0.24% +0.018 pp | 0.02% +0.006 pp | USD71.68 +219.6% | 31 qtrs — |
| 64 | EVERSEPT PARTNERS, LP | 334.5K -185.2K (-35.6%) | 76.63M -7.0M (-8.4%) | 0.24% -0.137 pp | 3.86% -1.903 pp | USD44.18 +418.5% | 20 qtrs — |
| 65 | AMUNDI | 333.2K +66.5K (+24.9%) | 76.34M +30.9M (+68.0%) | 0.24% +0.047 pp | 0.02% +0.006 pp | USD140.49 +63.1% | 19 qtrs — |
| 66 | ALLIANCEBERNSTEIN L.P. | 332.2K -9.8K (-2.9%) | 76.09M +21.1M (+38.3%) | 0.24% -0.009 pp | 0.02% +0.007 pp | USD49.89 +359.2% | 39 qtrs — |
| 67 | ZEVENBERGEN CAPITAL INVESTMENTS LLC | 323.6K -71.0K (-18.0%) | 74.13M +10.6M (+16.7%) | 0.24% -0.053 pp | 1.65% +0.414 pp | USD57.17 +300.7% | 12 qtrs — |
| 68 | FIRST TRUST ADVISORS LP | 319.7K -89.3K (-21.8%) | 73.25M +7.4M (+11.3%) | 0.23% -0.067 pp | 0.05% +0.004 pp | USD88.24 +159.6% | 25 qtrs — |
| 69 | PRINCIPAL FINANCIAL GROUP INC | 319.5K -109.8K (-25.6%) | 73.19M +4.1M (+5.9%) | 0.23% -0.082 pp | 0.04% +0.003 pp | USD51.49 +344.9% | 42 qtrs — |
| 70 | TWO SIGMA ADVISERS, LP | 307.7K +211.0K (+218.2%) | 70.49M +54.9M (+352.9%) | 0.22% +0.153 pp | 0.14% +0.106 pp | USD195.55 +17.2% | 7 qtrs — |
| 71 | DEUTSCHE BANK AG\ | 284.5K +18.8K (+7.1%) | 65.18M +22.4M (+52.4%) | 0.21% +0.013 pp | 0.02% +0.007 pp | USD145.11 +57.9% | 42 qtrs — |
| 72 | KINETIC PARTNERS MANAGEMENT, LP | 273.3K +273.3K (+100.0%) | 62.61M +62.6M (+100.0%) | 0.20% +0.199 pp | 3.04% +3.037 pp | USD229.09 +0.0% | 1 qtrs NEW |
| 73 | TUDOR INVESTMENT CORP ET AL | 271.4K +252.2K (+1,312.2%) | 62.18M +59.1M (+1,909.9%) | 0.20% +0.184 pp | 0.12% +0.110 pp | USD224.27 +2.1% | 2 qtrs — |
| 74 | TWO SIGMA INVESTMENTS, LP | 267.2K -14.3K (-5.1%) | 61.22M +15.9M (+35.1%) | 0.19% -0.012 pp | 0.09% +0.019 pp | USD150.80 +51.9% | 31 qtrs — |
| 75 | MILLENNIUM MANAGEMENT LLC | 245.1K -282.8K (-53.6%) | 56.15M -28.8M (-33.9%) | 0.18% -0.208 pp | 0.02% -0.013 pp | USD129.14 +77.4% | 42 qtrs — |
| 76 | ROYAL BANK OF CANADA | 244.0K -76.6K (-23.9%) | 55.90M +4.3M (+8.3%) | 0.18% -0.057 pp | 0.01% +0.001 pp | USD118.65 +93.1% | 42 qtrs — |
| 77 | GW&K INVESTMENT MANAGEMENT, LLC | 244.0K -169.5K (-41.0%) | 55.89M -10.7M (-16.0%) | 0.18% -0.125 pp | 0.48% -0.106 pp | USD122.07 +87.7% | 11 qtrs — |
| 78 | ROKOS CAPITAL MANAGEMENT LLP | 242.9K -63.6K (-20.8%) | 55.63M +6.3M (+12.8%) | 0.18% -0.048 pp | 0.22% +0.005 pp | USD141.41 +62.0% | 4 qtrs — |
| 79 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 223.5K -188.0 (-0.1%) | 51.19M +15.2M (+42.2%) | 0.16% -0.001 pp | 0.03% +0.008 pp | USD77.01 +197.5% | 27 qtrs — |
| 80 | NOMURA ASSET MANAGEMENT CO LTD | 218.2K -4.9K (-2.2%) | 49.99M +14.1M (+39.2%) | 0.16% -0.005 pp | 0.13% +0.033 pp | USD158.05 +44.9% | 4 qtrs — |
| 81 | NATIONAL PENSION SERVICE | 217.8K +208.6K (+2,249.4%) | 49.90M +48.4M (+3,243.6%) | 0.16% +0.152 pp | 0.04% +0.036 pp | USD226.19 +1.3% | 2 qtrs — |
| 82 | IEQ CAPITAL, LLC | 209.8K +57.0K (+37.3%) | 48.05M +23.5M (+95.5%) | 0.15% +0.041 pp | 0.14% +0.069 pp | USD179.23 +27.8% | 8 qtrs — |
| 83 | ENVESTNET ASSET MANAGEMENT INC | 205.9K +16.6K (+8.8%) | 47.16M +16.7M (+54.8%) | 0.15% +0.011 pp | 0.01% +0.005 pp | USD93.25 +145.7% | 27 qtrs — |
| 84 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 201.9K -808.0 (-0.4%) | 46.26M +13.6M (+41.8%) | 0.15% -0.002 pp | 0.05% +0.013 pp | USD94.85 +141.5% | 42 qtrs — |
| 85 | NEUBERGER BERMAN GROUP LLC | 197.1K +8.6K (+4.6%) | 45.15M +14.8M (+48.8%) | 0.14% +0.006 pp | 0.03% +0.011 pp | USD74.72 +206.6% | 21 qtrs — |
| 86 | JENNISON ASSOCIATES LLC | 195.9K -144.4K (-42.4%) | 44.89M -9.9M (-18.1%) | 0.14% -0.107 pp | 0.03% -0.005 pp | USD90.76 +152.4% | 9 qtrs — |
| 87 | AUSTRALIANSUPER PTY LTD | 195.4K +— (+0.0%) | 44.76M +13.3M (+42.3%) | 0.14% -0.001 pp | 0.21% +0.064 pp | USD168.89 +35.6% | 3 qtrs — |
| 88 | RENAISSANCE TECHNOLOGIES LLC | 190.6K -107.9K (-36.1%) | 43.66M -4.4M (-9.1%) | 0.14% -0.080 pp | 0.07% +0.004 pp | USD124.21 +84.4% | 10 qtrs — |
| 89 | EAGLE HEALTH INVESTMENTS LP | 183.3K -20.4K (-10.0%) | 41.98M +9.2M (+28.1%) | 0.13% -0.016 pp | 9.23% +0.620 pp | USD56.06 +308.7% | 21 qtrs — |
| 90 | CAPITAL IMPACT ADVISORS, LLC | 178.6K +113.5K (+174.5%) | 40.91M +30.4M (+290.6%) | 0.13% +0.083 pp | 3.20% +0.858 pp | USD199.16 +15.0% | 4 qtrs — |
| 91 | SEI INVESTMENTS CO | 176.3K -14.0K (-7.3%) | 40.38M +9.8M (+31.9%) | 0.13% -0.011 pp | 0.04% +0.007 pp | USD60.51 +278.6% | 31 qtrs — |
| 92 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 166.1K +149.0K (+870.9%) | 38.06M +35.3M (+1,282.0%) | 0.12% +0.109 pp | 0.04% +0.037 pp | USD222.16 +3.1% | 4 qtrs — |
| 93 | RHUMBLINE ADVISERS | 166.1K -499.0 (-0.3%) | 38.06M +11.2M (+41.9%) | 0.12% -0.001 pp | 0.03% +0.009 pp | USD65.43 +250.1% | 39 qtrs — |
| 94 | CIBC PRIVATE WEALTH GROUP, LLC | 163.5K -9.6K (-5.5%) | 37.46M +9.6M (+34.4%) | 0.12% -0.008 pp | 0.06% +0.016 pp | USD165.47 +38.4% | 9 qtrs — |
| 95 | HANDELSBANKEN FONDER AB | 161.0K +29.7K (+22.6%) | 36.88M +15.7M (+74.5%) | 0.12% +0.021 pp | 0.11% +0.044 pp | USD136.52 +67.8% | 23 qtrs — |
| 96 | TD ASSET MANAGEMENT INC | 157.5K +27.9K (+21.5%) | 36.07M +15.2M (+72.9%) | 0.11% +0.020 pp | 0.03% +0.012 pp | USD156.76 +46.1% | 7 qtrs — |
| 97 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 157.6K -1.6K (-1.0%) | 36.06M +10.4M (+40.7%) | 0.11% -0.002 pp | 0.02% +0.006 pp | USD141.41 +62.0% | 10 qtrs — |
| 98 | ENSIGN PEAK ADVISORS, INC | 153.3K -46.4K (-23.2%) | 35.13M +3.0M (+9.3%) | 0.11% -0.035 pp | 0.06% +0.009 pp | USD122.11 +87.6% | 25 qtrs — |
| 99 | ARTEMIS INVESTMENT MANAGEMENT LLP | 153.3K -65.3K (-29.9%) | 35.12M -65.7K (-0.2%) | 0.11% -0.049 pp | 0.42% -0.014 pp | USD118.42 +93.5% | 14 qtrs — |
| 100 | BARCLAYS PLC | 152.9K +12.8K (+9.1%) | 35.03M +17.2M (+96.9%) | 0.11% +0.009 pp | 0.01% +0.004 pp | USD129.06 +77.5% | 38 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.29
Bearish
Ratio by volume
0.47
Bearish
Buys
14
Sells
49
Shares acquired
62.3K
Shares disposed
132.5K
Cash buys
—
Cash sales
47.00
Net activity
-70,219
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2029-06-23 | Brophy Michael Burkes | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 37,500 | — | ↗ |
| 2029-06-08 | Brophy Michael Burkes | Officer | M-Exempt | D | Restricted Stock Units | 25,000 | 0.00 | — | 50,000 | — | ↗ |
| 2026-05-05 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 2,887 | 206.77 | 596.9K | 2,379,553 | D | ↗ |
| 2026-05-04 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 722 | 206.16 | 148.8K | 2,382,440 | D | ↗ |
| 2026-05-04 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 482 | 210.49 | 101.5K | 57,496 | D | ↗ |
| 2026-05-01 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 107 | 206.16 | 22.1K | 255,652 | D | ↗ |
| 2026-05-01 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 330 | 206.16 | 68.0K | 222,694 | D | ↗ |
| 2026-05-01 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 865 | 204.47 | 176.9K | 142,845 | D | ↗ |
| 2026-05-01 | Fesko John | Officer | S-Sale | D | Common Stock | 291 | 206.16 | 60.0K | 187,220 | D | ↗ |
| 2026-05-01 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 902 | 206.16 | 186.0K | 149,867 | D | ↗ |
| 2026-05-01 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 313 | 206.16 | 64.5K | 57,978 | D | ↗ |
| 2026-04-29 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 2,266 | 196.22 | 444.6K | 256,516 | D | ↗ |
| 2026-04-29 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 1,070 | 194.82 | 208.5K | 58,491 | D | ↗ |
| 2026-04-27 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 188 | 204.39 | 38.4K | 258,782 | D | ↗ |
| 2026-04-27 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 873 | 203.75 | 177.9K | 224,012 | D | ↗ |
| 2026-04-27 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,185 | 204.39 | 242.2K | 145,700 | D | ↗ |
| 2026-04-27 | Fesko John | Officer | S-Sale | D | Common Stock | 917 | 204.39 | 187.4K | 187,511 | D | ↗ |
| 2026-04-27 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 3,566 | 204.39 | 728.9K | 150,769 | D | ↗ |
| 2026-04-27 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 771 | 203.75 | 157.1K | 62,583 | D | ↗ |
| 2026-04-24 | Williams Brinkley Ruth | Director | A-Award | A | Common Stock | 86 | 0.00 | — | 5,475 | D | ↗ |
| 2026-04-24 | Rubin Eric H | Director | A-Award | A | Common Stock | 5 | 0.00 | — | 5 | D | ↗ |
| 2026-04-24 | ROSENMAN HERM | Director | A-Award | A | Common Stock | 117 | 0.00 | — | 20,558 | D | ↗ |
| 2026-04-24 | Marcus Gail Boxer | Director | A-Award | A | Common Stock | 108 | 0.00 | — | 5,961 | D | ↗ |
| 2026-04-24 | Chapman Rowan E | Director | A-Award | A | Common Stock | 114 | 0.00 | — | 5,866 | D | ↗ |
| 2026-04-24 | Bertagnolli Monica | Director | A-Award | A | Common Stock | 83 | 0.00 | — | 5,374 | D | ↗ |
| 2026-04-24 | Baynes Roy D. | Director | A-Award | A | Common Stock | 83 | 0.00 | — | 18,512 | D | ↗ |
| 2026-04-24 | BOTHA ROELOF | Director | A-Award | A | Common Stock | 222 | 0.00 | — | 2,894 | D | ↗ |
| 2026-04-17 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 750 | 199.66 | 149.7K | 20,282 | I | ↗ |
| 2026-04-06 | Rabinowitz Matthew | Director / Officer | M-Exempt | A | Common Stock | 58,292 | 9.59 | 559.0K | 2,410,772 | D | ↗ |
| 2026-04-01 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,909 | 205.00 | 391.3K | 224,885 | D | ↗ |
| 2026-04-01 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 952 | 203.31 | 193.6K | 147,882 | D | ↗ |
| 2026-03-31 | Rabinowitz Matthew | Director / Officer | M-Exempt | A | Common Stock | 41,708 | 9.59 | 400.0K | 2,352,480 | D | ↗ |
| 2026-03-26 | Rubin Eric H | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-20 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 235 | 199.88 | 47.0K | 21,312 | I | ↗ |
| 2026-03-18 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 1,814 | 198.65 | 360.4K | 259,255 | D | ↗ |
| 2026-03-16 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 100 | 190.07 | 19.0K | 2,360,672 | D | ↗ |
| 2026-03-13 | Rabinowitz Matthew | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 75,000 | 9.59 | 719.3K | 150,000 | D | ↗ |
| 2026-03-13 | Chapman Rowan E | Director | S-Sale | D | Common Stock | 122 | 191.38 | 23.3K | 5,752 | D | ↗ |
| 2026-03-12 | Rabinowitz Matthew | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 75,000 | 9.59 | 719.3K | 225,000 | D | ↗ |
| 2026-03-10 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 127 | 204.13 | 25.9K | 262,325 | D | ↗ |
| 2026-03-10 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,745 | 204.13 | 356.2K | 233,285 | D | ↗ |
| 2026-03-10 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 915 | 204.13 | 186.8K | 150,882 | D | ↗ |
| 2026-03-10 | Fesko John | Officer | S-Sale | D | Common Stock | 707 | 204.13 | 144.3K | 189,199 | D | ↗ |
| 2026-03-10 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 5,623 | 204.13 | 1.15M | 156,607 | D | ↗ |
| 2026-03-10 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 785 | 204.13 | 160.2K | 63,354 | D | ↗ |
| 2026-03-09 | Sheena Jonathan | Director | A-Award | A | Common Stock | 258 | 0.00 | — | 262,452 | D | ↗ |
| 2026-03-09 | RABINOWITZ DANIEL | Officer | A-Award | A | Common Stock | 1,745 | 0.00 | — | 235,030 | D | ↗ |
| 2026-03-09 | Moshkevich Solomon | Officer | A-Award | A | Common Stock | 1,774 | 0.00 | — | 151,797 | D | ↗ |
| 2026-03-09 | Fesko John | Officer | A-Award | A | Common Stock | 1,774 | 0.00 | — | 189,906 | D | ↗ |
| 2026-03-09 | Chapman Steven Leonard | Director / Officer | A-Award | A | Common Stock | 5,623 | 0.00 | — | 162,230 | D | ↗ |
| 2026-03-09 | Brophy Michael Burkes | Officer | A-Award | A | Common Stock | 1,968 | 0.00 | — | 64,139 | D | ↗ |
| 2026-03-06 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,998 | 198.04 | 395.7K | 233,285 | D | ↗ |
| 2026-03-02 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 100 | 202.85 | 20.3K | 262,194 | D | ↗ |
| 2026-03-02 | Moshkevich Solomon | Officer | M-Exempt | D | Stock Option (right to buy) | 5,125 | 9.59 | 49.1K | 0 | D | ↗ |
| 2026-03-02 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 2,463 | 200.24 | 493.2K | 156,972 | D | ↗ |
| 2026-02-27 | Sheena Jonathan | Director | A-Award | A | Common Stock | 2,103 | 0.00 | — | 265,264 | D | ↗ |
| 2026-02-27 | Rabinowitz Matthew | Director / Officer | A-Award | A | Common Stock | 29,920 | 0.00 | — | 2,310,772 | D | ↗ |
| 2026-02-27 | RABINOWITZ DANIEL | Officer | A-Award | A | Common Stock | 12,272 | 0.00 | — | 236,085 | D | ↗ |
| 2026-02-27 | Moshkevich Solomon | Officer | A-Award | A | Common Stock | 10,051 | 0.00 | — | 147,898 | D | ↗ |
| 2026-02-27 | Fesko John | Officer | A-Award | A | Common Stock | 10,051 | 0.00 | — | 188,132 | D | ↗ |
| 2026-02-27 | Chapman Steven Leonard | Director / Officer | A-Award | A | Common Stock | 37,401 | 0.00 | — | 160,557 | D | ↗ |
| 2026-02-27 | Brophy Michael Burkes | Officer | A-Award | A | Common Stock | 10,051 | 0.00 | — | 62,171 | D | ↗ |
| 2026-02-03 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 435 | 230.77 | 100.4K | 263,161 | D | ↗ |
| 2026-02-03 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,334 | 230.77 | 307.8K | 223,813 | D | ↗ |
| 2026-02-03 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,639 | 230.77 | 378.2K | 137,847 | D | ↗ |
| 2026-02-03 | Fesko John | Officer | S-Sale | D | Common Stock | 2,415 | 231.14 | 558.2K | 178,081 | D | ↗ |
| 2026-02-03 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 4,725 | 230.77 | 1.09M | 123,156 | D | ↗ |
| 2026-02-03 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 4,971 | 227.45 | 1.13M | 52,120 | D | ↗ |
| 2026-02-02 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 80 | 228.50 | 18.3K | 142,406 | D | ↗ |
| 2026-02-02 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 9,197 | 232.41 | 2.14M | 135,426 | D | ↗ |
| 2026-01-30 | Williams Brinkley Ruth | Director | A-Award | A | Common Stock | 73 | 0.00 | — | 5,389 | D | ↗ |
| 2026-01-30 | ROSENMAN HERM | Director | A-Award | A | Common Stock | 99 | 0.00 | — | 20,441 | D | ↗ |
| 2026-01-30 | Marcus Gail Boxer | Director | A-Award | A | Common Stock | 91 | 0.00 | — | 5,853 | D | ↗ |
| 2026-01-30 | Fesko John | Officer | A-Award | A | Common Stock | 6,135 | 0.00 | — | 181,675 | D | ↗ |
| 2026-01-30 | Chapman Rowan E | Director | A-Award | A | Common Stock | 97 | 0.00 | — | 5,874 | D | ↗ |
| 2026-01-30 | Bertagnolli Monica | Director | A-Award | A | Common Stock | 70 | 0.00 | — | 5,291 | D | ↗ |
| 2026-01-30 | Baynes Roy D. | Director | A-Award | A | Common Stock | 70 | 0.00 | — | 18,429 | D | ↗ |
| 2026-01-30 | BOTHA ROELOF | Director | A-Award | A | Common Stock | 112 | 0.00 | — | 2,540 | D | ↗ |
| 2026-01-29 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 876 | 230.92 | 202.3K | 59,059 | D | ↗ |
| 2026-01-28 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 191 | 237.66 | 45.4K | 263,596 | D | ↗ |
| 2026-01-28 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,000 | 237.66 | 237.7K | 225,147 | D | ↗ |
| 2026-01-28 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,200 | 237.66 | 285.2K | 142,486 | D | ↗ |
| 2026-01-28 | Fesko John | Officer | S-Sale | D | Common Stock | 928 | 237.66 | 220.6K | 175,540 | D | ↗ |
| 2026-01-28 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 3,648 | 237.66 | 867.0K | 213,180 | D | ↗ |
| 2026-01-28 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 1,176 | 237.44 | 279.2K | 60,926 | D | ↗ |
| 2026-01-27 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 291 | 240.53 | 70.0K | 263,787 | D | ↗ |
| 2026-01-27 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 886 | 240.53 | 213.1K | 226,147 | D | ↗ |
| 2026-01-27 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,013 | 240.53 | 243.7K | 143,686 | D | ↗ |
| 2026-01-27 | Fesko John | Officer | S-Sale | D | Common Stock | 784 | 240.53 | 188.6K | 176,468 | D | ↗ |
| 2026-01-27 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 2,322 | 240.53 | 558.5K | 216,828 | D | ↗ |
| 2026-01-27 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 784 | 240.53 | 188.6K | 63,339 | D | ↗ |
| 2026-01-23 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 160 | 242.31 | 38.8K | 22,372 | I | ↗ |
| 2026-01-21 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 2,470 | 234.12 | 578.3K | 264,678 | D | ↗ |
| 2026-01-21 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 438 | 235.00 | 102.9K | 227,033 | D | ↗ |
| 2026-01-21 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 293 | 235.00 | 68.9K | 144,699 | D | ↗ |
| 2026-01-21 | Fesko John | Officer | S-Sale | D | Common Stock | 339 | 235.00 | 79.7K | 177,252 | D | ↗ |
| 2026-01-21 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 1,590 | 235.00 | 373.7K | 219,150 | D | ↗ |
| 2026-01-21 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 36,573 | 242.67 | 8.88M | 64,123 | D | ↗ |
| 2026-01-20 | Sheena Jonathan | Director | M-Exempt | D | Restricted Stock Unit | 191 | 0.00 | — | 0 | D | ↗ |
| 2026-01-20 | RABINOWITZ DANIEL | Officer | M-Exempt | D | Restricted Stock Unit | 856 | 0.00 | — | 0 | D | ↗ |
| 2026-01-20 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 23,205 | 234.74 | 5.45M | 144,992 | D | ↗ |
| 2026-01-20 | Fesko John | Officer | S-Sale | D | Common Stock | 17,806 | 234.74 | 4.18M | 177,591 | D | ↗ |
| 2026-01-20 | Chapman Steven Leonard | Director / Officer | M-Exempt | D | Restricted Stock Unit | 3,386 | 0.00 | — | 0 | D | ↗ |
| 2026-01-20 | Brophy Michael Burkes | Officer | M-Exempt | D | Restricted Stock Unit | 1,522 | 0.00 | — | 0 | D | ↗ |
| 2026-01-14 | Sheena Jonathan | Director | A-Award | A | Common Stock | 7,450 | 0.00 | — | 270,031 | D | ↗ |
| 2026-01-14 | RABINOWITZ DANIEL | Officer | A-Award | A | Common Stock | 37,248 | 0.00 | — | 245,849 | D | ↗ |
| 2026-01-14 | Moshkevich Solomon | Officer | A-Award | A | Common Stock | 44,698 | 0.00 | — | 168,197 | D | ↗ |
| 2026-01-14 | Fesko John | Officer | A-Award | A | Common Stock | 44,698 | 0.00 | — | 195,397 | D | ↗ |
| 2026-01-14 | Chapman Steven Leonard | Director / Officer | A-Award | A | Common Stock | 152,718 | 0.00 | — | 289,286 | D | ↗ |
| 2026-01-14 | Brophy Michael Burkes | Officer | A-Award | A | Common Stock | 59,596 | 0.00 | — | 123,722 | D | ↗ |
| 2026-01-05 | Sheena Jonathan | Director | M-Exempt | D | Stock Option (right to buy) | 39,615 | 9.59 | 379.9K | 0 | D | ↗ |
| 2026-01-02 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,292 | 228.33 | 295.0K | 125,158 | D | ↗ |
| 2026-01-02 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 2,214 | 228.64 | 506.2K | 138,202 | D | ↗ |
| 2025-12-19 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 200 | 224.89 | 45.0K | 23,082 | I | ↗ |
| 2025-12-17 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 1,592 | 226.54 | 360.7K | 224,444 | D | ↗ |
| 2025-12-15 | Sheena Jonathan | Director | G-Gift | D | Common Stock | 1,060 | 0.00 | — | 226,036 | D | ↗ |
| 2025-12-15 | Moshkevich Solomon | Officer | G-Gift | D | Common Stock | 115 | 0.00 | — | 126,450 | D | ↗ |
| 2025-12-12 | ROSENMAN HERM | Director | S-Sale | D | Common Stock | 11,987 | 228.49 | 2.74M | 20,492 | D | ↗ |
| 2025-12-12 | Moshkevich Solomon | Officer | G-Gift | D | Common Stock | 180 | 0.00 | — | 108,881 | D | ↗ |
| 2025-12-10 | Moshkevich Solomon | Officer | M-Exempt | D | Stock Option (right to buy) | 22,376 | 9.59 | 214.6K | 5,125 | D | ↗ |
| 2025-12-09 | Sheena Jonathan | Director | M-Exempt | A | Common Stock | 4,436 | 9.29 | 41.2K | 227,096 | D | ↗ |
| 2025-12-05 | Chapman Rowan E | Director | M-Exempt | A | Common Stock | 4,000 | 32.15 | 128.6K | 10,143 | D | ↗ |
| 2025-12-04 | RABINOWITZ DANIEL | Officer | M-Exempt | A | Common Stock | 6,902 | 19.68 | 135.8K | 208,601 | D | ↗ |
| 2025-12-01 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 474 | 239.53 | 113.5K | 109,061 | D | ↗ |
| 2025-12-01 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 2,050 | 238.13 | 488.2K | 141,372 | D | ↗ |
| 2025-11-24 | BOTHA ROELOF | Director | S-Sale | D | Common Stock | 2,000 | 228.97 | 457.9K | 1,227,198 | I | ↗ |
| 2025-11-21 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 2,000 | 230.01 | 460.0K | 23,282 | I | ↗ |
| 2025-11-20 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 10,000 | 225.08 | 2.25M | 222,660 | D | ↗ |
| 2025-11-20 | Baynes Roy D. | Director | S-Sale | D | Common Stock | 1,884 | 224.89 | 423.7K | 18,359 | D | ↗ |
| 2025-11-19 | Baynes Roy D. | Director | S-Sale | D | Common Stock | 1,727 | 214.79 | 370.9K | 20,494 | D | ↗ |
| 2025-11-11 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 205 | 206.86 | 42.4K | 25,827 | I | ↗ |
| 2025-11-07 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 100 | 198.38 | 19.8K | 232,660 | D | ↗ |
| 2025-11-04 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 17,198 | 200.29 | 3.44M | 2,286,554 | D | ↗ |
| 2025-11-03 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 2,000 | 200.14 | 400.3K | 26,032 | I | ↗ |
| 2025-11-03 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 17,100 | 200.00 | 3.42M | 2,303,752 | D | ↗ |
| 2025-11-03 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 100 | 199.74 | 20.0K | 112,061 | D | ↗ |
| 2025-11-03 | Marcus Gail Boxer | Director | S-Sale | D | Common Stock | 122 | 198.71 | 24.2K | 5,762 | D | ↗ |
| 2025-11-03 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 1,915 | 198.96 | 381.0K | 301,389 | D | ↗ |
| 2025-10-31 | Williams Brinkley Ruth | Director | A-Award | A | Common Stock | 97 | 0.00 | — | 5,316 | D | ↗ |
| 2025-10-31 | ROSENMAN HERM | Director | A-Award | A | Common Stock | 132 | 0.00 | — | 68,761 | D | ↗ |
| 2025-10-31 | Marcus Gail Boxer | Director | A-Award | A | Common Stock | 121 | 0.00 | — | 5,884 | D | ↗ |
| 2025-10-31 | Chapman Rowan E | Director | A-Award | A | Common Stock | 128 | 0.00 | — | 6,143 | D | ↗ |
| 2025-10-31 | Bertagnolli Monica | Director | A-Award | A | Common Stock | 93 | 0.00 | — | 5,221 | D | ↗ |
| 2025-10-31 | Baynes Roy D. | Director | A-Award | A | Common Stock | 93 | 0.00 | — | 18,359 | D | ↗ |
| 2025-10-31 | BOTHA ROELOF | Director | A-Award | A | Common Stock | 149 | 0.00 | — | 6,839 | D | ↗ |
| 2025-10-29 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 300 | 188.37 | 56.5K | 65,693 | D | ↗ |
| 2025-10-28 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 191 | 191.46 | 36.6K | 235,730 | D | ↗ |
| 2025-10-28 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,058 | 191.46 | 202.6K | 201,699 | D | ↗ |
| 2025-10-28 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,198 | 191.46 | 229.4K | 115,061 | D | ↗ |
| 2025-10-28 | Fesko John | Officer | S-Sale | D | Common Stock | 928 | 191.46 | 177.7K | 150,699 | D | ↗ |
| 2025-10-28 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 3,680 | 191.46 | 704.6K | 149,840 | D | ↗ |
| 2025-10-28 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 404 | 191.51 | 77.4K | 66,193 | D | ↗ |
| 2025-10-27 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 288 | 192.32 | 55.4K | 235,921 | D | ↗ |
| 2025-10-27 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 935 | 192.32 | 179.8K | 202,757 | D | ↗ |
| 2025-10-27 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,008 | 192.32 | 193.9K | 116,259 | D | ↗ |
| 2025-10-27 | Fesko John | Officer | S-Sale | D | Common Stock | 781 | 192.32 | 150.2K | 151,627 | D | ↗ |
| 2025-10-27 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 2,335 | 192.32 | 449.1K | 153,520 | D | ↗ |
| 2025-10-27 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 781 | 192.32 | 150.2K | 68,408 | D | ↗ |
| 2025-10-24 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 755 | 196.77 | 148.6K | 69,189 | D | ↗ |
| 2025-10-23 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 495 | 187.16 | 92.6K | 69,944 | D | ↗ |
| 2025-10-22 | Brophy Michael Burkes | Officer | M-Exempt | D | Restricted Stock Unit | 1,250 | 0.00 | — | 0 | D | ↗ |
| 2025-10-21 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 93 | 187.95 | 17.5K | 236,209 | D | ↗ |
| 2025-10-21 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 464 | 187.95 | 87.2K | 203,692 | D | ↗ |
| 2025-10-21 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 292 | 187.95 | 54.9K | 117,267 | D | ↗ |
| 2025-10-21 | Fesko John | Officer | S-Sale | D | Common Stock | 339 | 187.95 | 63.7K | 152,408 | D | ↗ |
| 2025-10-21 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 1,603 | 187.95 | 301.3K | 155,855 | D | ↗ |
| 2025-10-21 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 602 | 187.95 | 113.1K | 70,109 | D | ↗ |
| 2025-10-20 | Sheena Jonathan | Director | M-Exempt | A | Common Stock | 190 | 0.00 | — | 236,302 | D | ↗ |
| 2025-10-20 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 10,000 | 190.00 | 1.90M | 5,000 | I | ↗ |
| 2025-10-20 | RABINOWITZ DANIEL | Officer | M-Exempt | D | Restricted Stock Unit | 856 | 0.00 | — | 856 | D | ↗ |
| 2025-10-20 | Chapman Steven Leonard | Director / Officer | M-Exempt | D | Restricted Stock Unit | 3,386 | 0.00 | — | 3,386 | D | ↗ |
| 2025-10-20 | Brophy Michael Burkes | Officer | M-Exempt | D | Restricted Stock Unit | 1,522 | 0.00 | — | 1,522 | D | ↗ |
| 2025-10-17 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 337 | 179.29 | 60.4K | 28,032 | I | ↗ |
| 2025-10-15 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 988 | 175.90 | 173.8K | 236,535 | D | ↗ |
| 2025-10-01 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 780 | 160.70 | 125.3K | 117,559 | D | ↗ |
| 2025-10-01 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 634 | 158.84 | 100.7K | 167,521 | D | ↗ |
| 2025-09-30 | RABINOWITZ DANIEL | Officer | S-Sale | D | Common Stock | 1,364 | 162.05 | 221.0K | 203,300 | D | ↗ |
| 2025-09-30 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 9,109 | 162.05 | 1.48M | 168,155 | D | ↗ |
| 2025-09-30 | Brophy Michael Burkes | Officer | S-Sale | D | Common Stock | 2,491 | 162.05 | 403.7K | 69,189 | D | ↗ |
| 2025-09-29 | RABINOWITZ DANIEL | Officer | M-Exempt | D | Restricted Stock Unit | 2,500 | 0.00 | — | 0 | D | ↗ |
| 2025-09-29 | Chapman Steven Leonard | Director / Officer | M-Exempt | A | Common Stock | 18,750 | 0.00 | — | 177,264 | D | ↗ |
| 2025-09-29 | Brophy Michael Burkes | Officer | M-Exempt | A | Common Stock | 6,250 | 0.00 | — | 71,680 | D | ↗ |
| 2025-09-19 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 1,518 | 180.06 | 273.3K | 29,162 | I | ↗ |
| 2025-09-19 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 1,188 | 181.28 | 215.4K | 2,320,852 | D | ↗ |
| 2025-09-18 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 14,473 | 180.13 | 2.61M | 2,346,379 | D | ↗ |
| 2025-09-17 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 256 | 176.61 | 45.2K | 239,182 | D | ↗ |
| 2025-09-15 | Moshkevich Solomon | Officer | G-Gift | D | Common Stock | 300 | 0.00 | — | 120,559 | D | ↗ |
| 2025-09-12 | Rabinowitz Matthew | Director / Officer | S-Sale | D | Common Stock | 4,500 | 170.31 | 766.4K | 25,500 | I | ↗ |
| 2025-09-02 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 1,290 | 165.69 | 213.7K | 122,569 | D | ↗ |
| 2025-09-02 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 1,907 | 167.69 | 319.8K | 158,514 | D | ↗ |
| 2025-08-28 | Chapman Rowan E | Director | S-Sale | D | Common Stock | 2,750 | 166.99 | 459.2K | 6,015 | D | ↗ |
| 2025-08-14 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 867 | 155.46 | 134.8K | 123,867 | D | ↗ |
| 2025-08-14 | Fesko John | Officer | S-Sale | D | Common Stock | 672 | 155.46 | 104.5K | 152,753 | D | ↗ |
| 2025-08-12 | Moshkevich Solomon | Officer | A-Award | A | Common Stock | 1,675 | 0.00 | — | 124,734 | D | ↗ |
| 2025-08-12 | Fesko John | Officer | A-Award | A | Common Stock | 1,675 | 0.00 | — | 153,425 | D | ↗ |
| 2025-08-11 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 180 | 152.40 | 27.4K | 35,182 | I | ↗ |
| 2025-08-08 | Sheena Jonathan | Director | S-Sale | D | Common Stock | 800 | 163.88 | 131.1K | 242,452 | D | ↗ |
| 2025-08-01 | Moshkevich Solomon | Officer | S-Sale | D | Common Stock | 100 | 134.08 | 13.4K | 123,059 | D | ↗ |
| 2025-08-01 | Marcus Gail Boxer | Director | S-Sale | D | Common Stock | 1,183 | 133.66 | 158.1K | 5,763 | D | ↗ |
| 2025-08-01 | Chapman Steven Leonard | Director / Officer | S-Sale | D | Common Stock | 2,997 | 133.31 | 399.5K | 163,593 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-59.7K
Shares Outstanding
141.73M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Steven Chapman Chief Executive Officer and President | 853.7K | — | 12.98M | — | 1.11M | 9.9K | 14.96M | 86.78% | ↗ |
| 2 | 2025 | Matthew Rabinowitz Executive Chairman | 426.4K | — | 10.38M | — | 473.5K | — | 11.28M | 92.02% | ↗ |
| 3 | 2025 | Michael Brophy Chief Financial Officer | 562.8K | — | 4.50M | — | 390.2K | 6.2K | 5.46M | 82.43% | ↗ |
| 4 | 2025 | Solomon Moshkevich President, Clinical Diagnostics | 504.7K | — | 4.50M | — | 351.6K | 9.9K | 5.37M | 83.86% | ↗ |
| 5 | 2025 | John Fesko President, Chief Business Officer | 504.7K | — | 4.19M | — | 351.6K | 9.9K | 5.05M | 82.86% | ↗ |
| 6 | 2024 | Steven Chapman Chief Executive Officer and President | 799.9K | — | 11.28M | — | 938.4K | 9.9K | 13.03M | 86.59% | ↗ |
| 7 | 2024 | Steven Chapman Chief Executive Officer and President | 799.9K | — | 11.28M | — | 938.4K | 9.9K | 13.03M | 86.59% | ↗ |
| 8 | 2024 | Matthew Rabinowitz Executive Chairman | 401.5K | — | 9.03M | — | 405.1K | — | 9.83M | 91.80% | ↗ |
| 9 | 2024 | Matthew Rabinowitz Executive Chairman | 401.5K | — | 9.03M | — | 405.1K | — | 9.83M | 91.80% | ↗ |
| 10 | 2024 | Solomon Moshkevich President, Clinical Diagnostics | 490.0K | — | 4.10M | — | 285.6K | 9.9K | 4.89M | 83.93% | ↗ |
| 11 | 2024 | Solomon Moshkevich President, Clinical Diagnostics | 490.0K | — | 4.10M | — | 285.6K | 9.9K | 4.89M | 83.93% | ↗ |
| 12 | 2024 | John Fesko President, Chief Business Officer | 490.0K | — | 4.10M | — | 285.6K | 9.9K | 4.89M | 83.93% | ↗ |
| 13 | 2024 | John Fesko President, Chief Business Officer | 490.0K | — | 4.10M | — | 285.6K | 9.9K | 4.89M | 83.93% | ↗ |
| 14 | 2024 | Michael Brophy Chief Financial Officer | 493.3K | — | 4.10M | — | 284.5K | 6.2K | 4.89M | 83.96% | ↗ |
| 15 | 2024 | Michael Brophy Chief Financial Officer | 493.3K | — | 4.10M | — | 284.5K | 6.2K | 4.89M | 83.96% | ↗ |
| 16 | 2023 | Steven Chapman Chief Executive Officer and President | 751.1K | — | 11.13M | — | 833.8K | 9.9K | 12.73M | 87.47% | ↗ |
| 17 | 2023 | Steven Chapman Chief Executive Officer and President | 751.1K | — | 11.13M | — | 833.8K | 9.9K | 12.73M | 87.47% | ↗ |
| 18 | 2023 | Matthew Rabinowitz Executive Chairman | 401.5K | — | — | 8.20M | 366.9K | — | 8.97M | 91.43% | ↗ |
| 19 | 2023 | Matthew Rabinowitz Executive Chairman | 401.5K | — | — | 8.20M | 366.9K | — | 8.97M | 91.43% | ↗ |
| 20 | 2023 | Michael Brophy Chief Financial Officer | 465.3K | — | 4.34M | — | 252.6K | 6.7K | 5.07M | 85.71% | ↗ |
| 21 | 2023 | Michael Brophy Chief Financial Officer | 465.3K | — | 4.34M | — | 252.6K | 6.7K | 5.07M | 85.71% | ↗ |
| 22 | 2023 | Daniel Rabinowitz Chief Legal Officer | 407.6K | — | 2.72M | — | 193.1K | 9.9K | 3.33M | 81.64% | ↗ |
| 23 | 2023 | Robert Schueren Chief Operating Officer | 274.5K | — | 1.74M | — | 146.7K | 8.0K | 2.17M | 80.20% | ↗ |
| 24 | 2022 | Steve Chapman Chief Executive Officer and President | 609.6K | — | 7.09M | — | 533.8K | 9.2K | 8.25M | 86.02% | ↗ |
| 25 | 2022 | Steven Chapman Chief Executive Officer and President | 609.6K | — | 7.09M | — | 533.8K | 9.2K | 8.25M | 86.02% | ↗ |
| 26 | 2022 | Matthew Rabinowitz Executive Chairman | 300.9K | — | — | 7.76M | 140.7K | — | 8.20M | 94.62% | ↗ |
| 27 | 2022 | Robert Schueren Chief Operating Officer | 431.9K | — | 3.19M | — | 206.1K | 7.0K | 3.83M | 83.17% | ↗ |
| 28 | 2022 | Michael Brophy Chief Financial Officer | 407.7K | — | 3.19M | — | 194.9K | 8.7K | 3.80M | 83.91% | ↗ |
| 29 | 2022 | Daniel Rabinowitz Chief Legal Officer | 394.7K | — | 1.79M | — | 162.2K | 9.2K | 2.36M | 76.01% | ↗ |
| 30 | 2021 | Steven Chapman Chief Executive Officer and President | 525.7K | — | 14.03M | 8.39M | 391.2K | 8.7K | 23.34M | 96.03% | ↗ |
| 31 | 2021 | Steve Chapman Chief Executive Officer and President | 525.7K | — | 14.03M | 8.39M | 391.2K | 8.7K | 23.34M | 96.03% | ↗ |
| 32 | 2021 | Matthew Rabinowitz Executive Chairman | 334.0K | — | — | 9.63M | 168.2K | — | 10.13M | 95.04% | ↗ |
| 33 | 2021 | Robert Schueren Chief Operating Officer | 464.8K | — | 9.10M | — | 233.3K | 8.7K | 9.80M | 92.79% | ↗ |
| 34 | 2021 | Michael Brophy Chief Financial Officer | 436.7K | — | 9.10M | — | 216.2K | 8.5K | 9.76M | 93.22% | ↗ |
| 35 | 2021 | Daniel Rabinowitz Chief Legal Officer | 379.3K | — | 3.42M | — | 169.5K | 8.7K | 3.97M | 85.97% | ↗ |
| 36 | 2020 | Steve Chapman Chief Executive Officer and President | 486.7K | — | 5.54M | 1.75M | 296.9K | 8.6K | 8.08M | 90.20% | ↗ |
| 37 | 2020 | Matthew Rabinowitz Executive Chairman | 334.0K | — | — | 3.30M | 180.3K | — | 3.81M | 86.51% | ↗ |
| 38 | 2020 | Robert Schueren Chief Operating Officer | 446.0K | — | 2.88M | — | 236.6K | 8.6K | 3.57M | 80.65% | ↗ |
| 39 | 2020 | Michael Brophy Chief Financial Officer | 409.2K | — | 2.51M | — | 214.2K | 8.4K | 3.14M | 79.88% | ↗ |
| 40 | 2020 | Jonathan Sheena Founder, Director, and Former Chief Technology Officer | 201.4K | — | 364.1K | — | 84.2K | 8.3K | 658.0K | 55.33% | ↗ |
| 41 | 2019 | Steve Chapman Chief Executive Officer and President | 450.8K | — | 3.02M | 2.50M | 218.8K | 11.4K | 6.20M | 89.02% | ↗ |
| 42 | 2019 | Robert Schueren Chief Operating Officer | 410.8K | — | 2.80M | 696.2K | 200.2K | 8.2K | 4.11M | 84.94% | ↗ |
| 43 | 2019 | Michael Brophy Chief Financial Officer | 354.0K | — | 2.61M | 415.0K | 157.3K | 10.3K | 3.54M | 85.27% | ↗ |
| 44 | 2019 | Matthew Rabinowitz Executive Chairman | 334.8K | — | 129.8K | 1.89M | 162.4K | — | 2.51M | 80.23% | ↗ |
| 45 | 2019 | Matthew Rabinowitz former Chief Executive Officer and President and current Executive Chairman | 334.8K | — | 129.8K | 1.89M | 162.4K | — | 2.51M | 80.23% | ↗ |
| 46 | 2019 | Jonathan Sheena Founder, Director, and Former Chief Technology Officer | 206.0K | — | 274.0K | 181.6K | 79.2K | 11.9K | 752.7K | 60.52% | ↗ |
| 47 | 2019 | Jonathan Sheena Chief Technology Officer | 206.0K | — | 274.0K | 181.6K | 79.2K | 11.9K | 752.7K | 60.52% | ↗ |
| 48 | 2018 | Matthew Rabinowitz former Chief Executive Officer and President and current Executive Chairman | 500.0K | 110.5K | 469.4K | 4.07M | 213.1K | — | 5.37M | 84.66% | ↗ |
| 49 | 2018 | Matthew Rabinowitz Executive Chairman | 500.0K | 110.5K | 469.4K | 4.07M | 213.1K | — | 5.37M | 84.66% | ↗ |
| 50 | 2018 | Matthew Rabinowitz Chief Executive Officer, President, and Chairman | 500.0K | 110.5K | 469.4K | 4.07M | 213.1K | — | 5.37M | 84.66% | ↗ |
| 51 | 2018 | Steve Chapman Chief Executive Officer and President | 372.9K | 32.1K | 341.3K | 570.0K | 166.9K | — | 1.48M | 61.44% | ↗ |
| 52 | 2018 | Steve Chapman Chief Operating Officer | 372.9K | 32.1K | 341.3K | 570.0K | 166.9K | — | 1.48M | 61.44% | ↗ |
| 53 | 2018 | Michael Brophy Chief Financial Officer | 340.0K | 52.5K | 449.0K | 188.0K | 136.5K | — | 1.17M | 54.63% | ↗ |
| 54 | 2017 | Matthew Rabinowitz Chief Executive Officer, President, and Chairman | 505.4K | — | — | 2.42M | 77.0K | — | 2.29M | 105.67% | ↗ |
| 55 | 2017 | Matthew Rabinowitz former Chief Executive Officer and President and current Executive Chairman | 505.4K | — | — | 2.42M | 77.0K | — | 2.29M | 105.67% | ↗ |
| 56 | 2017 | Steve Chapman Chief Executive Officer and President | 368.6K | — | 186.1K | 908.3K | 164.2K | — | 1.63M | 67.26% | ↗ |
| 57 | 2017 | Steve Chapman Chief Operating Officer | 368.6K | — | 186.1K | 908.3K | 164.2K | — | 1.63M | 67.26% | ↗ |
| 58 | 2017 | Michael Brophy Chief Financial Officer | 329.8K | — | 186.1K | 611.3K | 66.3K | — | 1.19M | 66.81% | ↗ |
| 59 | 2016 | Matthew Rabinowitz Chief Executive Officer, President, and Chairman | 452.6K | — | — | 1.67M | 225.3K | — | 2.35M | 71.15% | ↗ |
| 60 | 2016 | Jonathan Sheena Chief Technology Officer | 321.0K | — | — | 552.1K | 117.1K | — | 990.2K | 55.75% | ↗ |
| 61 | 2016 | Herm Rosenman Chief Financial Officer | 288.3K | — | 575.4K | — | — | — | 863.7K | 66.62% | ↗ |
| 62 | 2015 | Matthew Rabinowitz Chief Executive Officer, President, and Chairman | 300.0K | 33.7K | — | 8.3K | — | — | 342.0K | 2.43% | ↗ |
| 63 | 2015 | Jonathan Sheena Chief Technology Officer | 300.0K | 33.7K | — | — | — | — | 333.7K | 0.00% | ↗ |
| 64 | 2015 | Herm Rosenman Chief Financial Officer | 275.0K | 32.5K | — | — | — | — | 307.5K | 0.00% | ↗ |
| 65 | 2014 | Matthew Rabinowitz Chief Executive Officer, President, and Chairman | 211.0K | 72.0K | — | 4.99M | — | 22.8K | 5.29M | 94.22% | ↗ |
| 66 | 2014 | Jonathan Sheena Chief Technology Officer | 211.0K | 72.0K | — | 1.94M | — | — | 2.22M | 87.28% | ↗ |
| 67 | 2014 | Herm Rosenman Chief Financial Officer | 245.9K | 48.5K | — | 301.0K | — | — | 595.5K | 50.55% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steven Leonard Chapman | Chief Executive Officer & Director | 2M | male |
| Michael Brophy | Chief Financial Officer | 959.2K | male |
| Matthew Rabinowitz | Co-Founder & Executive Chairman | 899.9K | — |
| John Fesko | President & Chief Business Officer | 866.2K | male |
| Solomon Moshkevich | President of Clinical Diagnostics | 866.2K | male |
| Daniel Rabinowitz | Secretary & Chief Legal Officer | 610.6K | male |
| Jonathan Sheena | Co-Founder & Director | 293.9K | male |
| Eric A. Evans | Chief Scientific Officer | — | male |
| Olesya A. Anisimova | Chief Accounting Officer | — | female |
| Phil Grinnell | Chief Sales Officer | — | male |
| Rishi Kacker | Chief Technology Officer | — | male |
| Jerry Diffley | Chief Compliance & Privacy Officer | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2021-04-20 | 2021-05-04 | Bill Hagerty | TN | Self | Sale (Partial) | $1,001 - $15,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-09-22 | 2025-10-16 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-22 | 2025-09-08 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-22 | 2025-08-12 | Josh Gottheimer | NJ05 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2024-11-20 | 2024-12-06 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-04-10 | 2023-05-19 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-03-06 | 2023-04-17 | Daniel Goldman | NY10 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NTRA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
